Bilypsa (Saroglitazar) 4 mg
Bilypsa (Saroglitazar 4 mg) is the world's first approved medication specifically for Non-Alcoholic Steatohepatitis (NASH).
Manufacturer: Zydus Lifesciences (India). It is a breakthrough therapeutic agent designed to treat "fatty liver" conditions not caused by alcohol consumption.
Mechanism of Action ("Dual PPAR Agonist"):
Saroglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist acting on both α (alpha) and γ (gamma) subtypes. The alpha action reduces high triglycerides and liver fat accumulation, while the gamma action improves insulin sensitivity and controls blood sugar. It effectively halts liver fibrosis and reduces inflammation.
✅ Key Benefit: Significant reduction in liver fat content and normalization of liver enzymes (ALT/AST).
Indicated for metabolic liver disorders:
- liver Non-Alcoholic Steatohepatitis (NASH): Liver inflammation and damage caused by a buildup of fat.
- 🩸 Non-Alcoholic Fatty Liver Disease (NAFLD): Particularly in patients with comorbidities like Type 2 Diabetes Mellitus or Dyslipidemia (high triglycerides).
Packaging: 4 mg Tablets (Pack of 45).
⚠️ ADMINISTRATION:
- 💊 Dosage: Standard dose is one tablet (4 mg) once daily.
- 🕒 Timing: Can be taken with or without food. Swallow whole with water.
- 📅 Duration: Long-term therapy is often required for liver regeneration; follow the physician's prescription.
- Pregnancy and breastfeeding (safety not established).
- Hypersensitivity to Saroglitazar or any excipients.
- Severe renal or hepatic impairment (requires medical supervision).
Generally well-tolerated, but side effects may include:
- 🤕 General: Asthenia (weakness), Pyrexia (mild fever).
- 🤢 Gastrointestinal: Gastritis, dyspepsia, abdominal discomfort.
- 🤧 Respiratory: Nasopharyngitis.
What Customers Say
No reviews yet
Your review can be the first!